• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测难治性心源性休克后接受静脉-动脉体外膜肺氧合治疗患者生存结局的列线图。

Nomogram to predict survival outcome of patients with veno-arterial extracorporeal membrane oxygenation after refractory cardiogenic shock.

机构信息

The Second School of Clinical Medicine, Southern Medical University, Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.

出版信息

Postgrad Med. 2022 Jan;134(1):37-46. doi: 10.1080/00325481.2021.1925562. Epub 2021 May 20.

DOI:10.1080/00325481.2021.1925562
PMID:33945393
Abstract

OBJECTIVE

: This study aims to develop a nomogram model to predict the survival of refractory cardiogenic shock (RCS) patients that received veno-arterial extracorporeal membrane oxygenation (VA-ECMO).

METHODS

A total of 235 and 209 RCS patients were supported with VA-ECMO from January 2018 to December 2019 in Guangdong Provincial People's Hospital, and from January 2020 to December 2020 in four third-grade and class-A hospitals were a development cohort (DC) and validation cohort (VC), respectively. Finally, 137 and 98 patients were included in the DC and VC. Multivariate logistic regression analysis was used to identify variables, and only these independent risk factors were used to establish the nomogram model. The receiver operating characteristic curve (ROC), calibration plot, decision curve, and clinical impact curves were used to evaluate the nomogram's discriminative ability, predictive accuracy, and clinical application value.

RESULTS

Pre-ECMO cardiogenic arrest (pre-ECA), lactate (Lac), inotropic score (IS), and modified nutrition risk in the critically ill score (mNUTRIC score) were incorporated into the nomogram. This showed good discrimination in the DC, with an area under ROC (AUROC) and a 95% confidence interval (CI) of 0.959 (0.911-0.986). The AUROC (95% CI) of the VC was 0.928 (0.858-0.971). The calibration plots of the DC and VC presented good calibration results. The decision curve and clinical impact curve of the nomogram provided improved benefits for RCS patients.

CONCLUSIONS

This study established a prediction nomogram composed of pre-ECA, Lac, IS, and mNUTRIC scores that could help clinicians to predict the survival probability at hospital discharge precisely and rapidly for RCS patients that received VA-ECMO.

摘要

目的

本研究旨在开发一种列线图模型,以预测接受静脉-动脉体外膜肺氧合(VA-ECMO)治疗的难治性心源性休克(RCS)患者的生存情况。

方法

2018 年 1 月至 2019 年 12 月,广东省人民医院共有 235 例 RCS 患者接受 VA-ECMO 支持,2020 年 1 月至 12 月,4 家三级甲等医院共有 209 例患者接受 VA-ECMO 支持,分别作为开发队列(DC)和验证队列(VC)。最终,DC 和 VC 分别纳入 137 例和 98 例患者。采用多变量逻辑回归分析识别变量,仅将这些独立风险因素纳入列线图模型。采用受试者工作特征曲线(ROC)、校准图、决策曲线和临床影响曲线评估列线图的区分能力、预测准确性和临床应用价值。

结果

列线图纳入了 ECMO 前心搏骤停(pre-ECA)、乳酸(Lac)、正性肌力评分(IS)和改良重症患者营养风险评分(mNUTRIC 评分)。该模型在 DC 中具有良好的区分能力,ROC 曲线下面积(AUROC)及其 95%置信区间(CI)为 0.959(0.911-0.986)。VC 的 AUROC(95%CI)为 0.928(0.858-0.971)。DC 和 VC 的校准图均呈现出良好的校准结果。列线图的决策曲线和临床影响曲线为 RCS 患者提供了更高的获益。

结论

本研究建立了一个由 pre-ECA、Lac、IS 和 mNUTRIC 评分组成的预测列线图,可帮助临床医生快速准确地预测接受 VA-ECMO 治疗的 RCS 患者出院时的生存概率。

相似文献

1
Nomogram to predict survival outcome of patients with veno-arterial extracorporeal membrane oxygenation after refractory cardiogenic shock.用于预测难治性心源性休克后接受静脉-动脉体外膜肺氧合治疗患者生存结局的列线图。
Postgrad Med. 2022 Jan;134(1):37-46. doi: 10.1080/00325481.2021.1925562. Epub 2021 May 20.
2
Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score.预测 ECMO 治疗难治性心源性休克后的生存率:静脉-动脉-体外膜肺氧合(VA-ECMO)后生存率评分(SAVE 评分)。
Eur Heart J. 2015 Sep 1;36(33):2246-56. doi: 10.1093/eurheartj/ehv194. Epub 2015 Jun 1.
3
Predicting mortality in patients undergoing VA-ECMO after coronary artery bypass grafting: the REMEMBER score.预测冠状动脉旁路移植术后行 VA-ECMO 患者的死亡率:REMMEMBER 评分。
Crit Care. 2019 Jan 11;23(1):11. doi: 10.1186/s13054-019-2307-y.
4
VA-ECMO Support in Nonsurgical Patients With Refractory Cardiogenic Shock: Pre-Implant Outcome Predictors.非手术难治性心源性休克患者的VA-ECMO支持:植入前结局预测因素
Artif Organs. 2019 Feb;43(2):132-141. doi: 10.1111/aor.13331. Epub 2018 Nov 6.
5
Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock post-cardiac arrest.心肺复苏后难治性心原性休克的静脉-动脉体外膜肺氧合治疗。
Intensive Care Med. 2016 Dec;42(12):1999-2007. doi: 10.1007/s00134-016-4541-y. Epub 2016 Sep 28.
6
Contemporary Use of Veno-Arterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Acute Coronary Syndrome.当代静脉-动脉体外膜肺氧合在急性冠状动脉综合征难治性心源性休克中的应用
J Invasive Cardiol. 2016 Feb;28(2):52-7. Epub 2015 Dec 15.
7
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for emergency cardiac support.静脉-动脉体外膜肺氧合(VA-ECMO)用于紧急心脏支持。
J Crit Care. 2018 Apr;44:31-38. doi: 10.1016/j.jcrc.2017.10.011. Epub 2017 Oct 12.
8
Blood Lactate as a Reliable Marker for Mortality of Pediatric Refractory Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation.血乳酸作为需要体外膜肺氧合的小儿难治性心源性休克死亡率的可靠标志物。
Pediatr Cardiol. 2019 Mar;40(3):602-609. doi: 10.1007/s00246-018-2033-2. Epub 2019 Jan 2.
9
Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the Extracorporeal Life Support Organizations' ECMO case registry.药物性心原性休克患者应用静脉-动脉体外膜肺氧合(VA-ECMO)的临床效果:体外生命支持组织 ECMO 病例登记库的一项回顾性研究。
Clin Toxicol (Phila). 2020 Jul;58(7):705-710. doi: 10.1080/15563650.2019.1676896. Epub 2019 Oct 16.
10
Prediction of In-Hospital Mortality for Ischemic Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation.需要静脉-动脉体外膜肺氧合的缺血性心源性休克患者院内死亡率的预测
J Am Heart Assoc. 2024 Feb 20;13(4):e032701. doi: 10.1161/JAHA.123.032701. Epub 2024 Feb 16.

引用本文的文献

1
Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Comprehensive Systematic Literature Review and Meta-Analyses.用于心源性休克患者的Impella与体外膜肺氧合(VA-ECMO):全面系统文献综述与荟萃分析
J Cardiovasc Dev Dis. 2023 Apr 5;10(4):158. doi: 10.3390/jcdd10040158.
2
Prognostic models for mortality risk in patients requiring ECMO.需要 ECMO 支持的患者死亡率风险预测模型。
Intensive Care Med. 2023 Feb;49(2):131-141. doi: 10.1007/s00134-022-06947-z. Epub 2023 Jan 4.
3
Evaluation of the discrimination and calibration of predictive scores of mortality in ECMO for patients with COVID-19.
评估 COVID-19 患者体外膜肺氧合(ECMO)死亡率预测评分的区分度和校准度。
Artif Organs. 2023 Jun;47(6):1007-1017. doi: 10.1111/aor.14493. Epub 2023 Jan 12.
4
Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing mA modification of Trio mRNA.下调的ALKBH5通过增加Trio mRNA的m⁶A修饰促进心肌缺血/再灌注损伤。
Ann Transl Med. 2022 Apr;10(7):417. doi: 10.21037/atm-22-1289.